Skip to main content
. Author manuscript; available in PMC: 2018 Apr 13.
Published in final edited form as: JAMA Dermatol. 2014 Dec;150(12):1331–1335. doi: 10.1001/jamadermatol.2014.1939

Figure 2. Immunophenotype of Repopulating B Cells 26 Months After the First Cycle of Veltuzumab Therapy.

Figure 2

A, CD19+ peripheral blood B-cell depletion and repopulation during the second cycle of veltuzumab therapy. B-cell subsets were analyzed at 26 months, shortly after relapse from long-term remission. B, Long-term remission after the first cycle of veltuzumab correlates with the elevation of naive (CD19+CD27−) compared with memory (CD19+CD27+) B-cell frequencies. C, Long-term remission after the first cycle of veltuzumab correlates with the high levels (12.5%) of transitional (CD19+CD24+CD38+) B cells, as previously described.2